MARKET WIRETradingView • 18h ago
Kewaunee Scientific Corporation Estimates – NASDAQ:KEQUTradingView report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
Why KEQU Stock slipped -0.21% Today — RQD Quant Desk Flash
$33.44 -0.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $33.36
Kewaunee Scientific Corporation (KEQU) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $96.8M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on KEQU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Kewaunee Scientific Corporation (NASDAQ: KEQU) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $33.44 (-0.21% 1D, market cap $96.8M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, KEQU ranks #87 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does KEQU compare to BNR and SERA in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), KEQU carries a Roarable C+ (69/100 RQD), trailing P/E of 10.1x, gross margin of 28.5%, and ROIC of 16.7%. By comparison, BNR (Burning Rock Biotech Limited) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $115.0M) and SERA (Sera Prognostics Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $80.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for KEQU?
▼
Per KEQU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000055529), Kewaunee Scientific Corporation generated $282.0M in revenue (+17.3% YoY), $9.6M in net income, and $18.6M in free cash flow against $176.0M in total assets and $16.3M in total debt. Key quantitative strengths: Strong cash generator (29% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $33.36 (-0.23%)🧬 Cannibal Buyback (-2.92% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 6.6% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C+ · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KEQU)Realized 20D OHLCV Swing Band: ±4.8%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY KEQU SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (26% of score)
SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-2.92% YoY Shares)
▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (25% of score)
SEC XBRL FY 2025 (10-K): 6.6% FCF Margin ($18.6M FCF) & 28.5% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$32.20+2.2% Next Q
61
Q2 (-2Q)Grade C+$32.92+0.9% Next Q
64
Q3 (-1Q)Grade B-$33.23+0.6% Next Q
66
CurrentGrade C+$33.44+2% Hist 90D α
69
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the KEQU Bull Thesis Could Fail
Even with a 69/100 (C+) score, KEQU faces multiple-compression risk if 10.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) — any gross margin slip below 26.0% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($34.46) or 200D SMA ($36.77) invalidates the momentum regime and cuts Target Base ($35.10) toward Bear Floor ($27.38).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $KEQU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KEQU Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KEQU Stock slipped -0.21% Today — RQD Quant Desk Flash
Kewaunee Scientific Corporation (KEQU) slipped -0.21% to $33.44, trading at 13% of its 52-week range ($32 – $43.36). Solid 29% profit margin (17% return on capital), mixed timing at 10x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 13% of its 52-week range ($32 – $43.36) with RSI-14 at 49.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±4.8% around $33.44 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 28.5% gross margin and $18.6M annual free cash flow.
Live KEQU Headlines & Catalysts
MARKET WIREYahoo Finance • 21h ago
The Zacks Analyst Blog Highlights Salesforce, S&P Global, Intuit, Kewaunee Scientific and Key TronicYahoo Finance report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
The U.S.'s largest lab dealer could join KewauneeStock Titan report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREInvesting.com India • 1d ago
Kewaunee Scientific to acquire lab dealer Nycom for $55M By Investing.comInvesting.com India report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
Avoiding Lag: Real-Time Signals in (KEQU) MovementStock Traders Daily report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A $30M cash payment at closing forms part of Kewaunee (KEQU)'s planned NYCOM acquisition.Stock Titan report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.dars.gov.et/ • 1d ago
Kewaunee Scientific (KEQU) Edges Higher to $32.79 as Buyers Defend Support - PCR Extremehttps://www.dars.gov.et/ report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 12d ago
Top Analyst Reports for Salesforce, S&P & IntuitSalesforce, S&P Global and Intuit navigate AI-driven growth opportunities, recurring revenue gains and strategic shifts while facing competition, cost pressures and execution risks.
MARKET WIREYahoo • 19h ago
Kewaunee Scientific Announces Agreement to Acquire Nycom, Inc.Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that it has entered into a definitive agreement to acquire Nycom, Inc. ("Nycom"), the largest lab dealer in the USA. The proposed acquisition represents an i
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (KEQU Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KEQU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.35%▼ DESCENDING CHANNEL
2026-11-03O $33.51H $33.51L $33.44C $33.44VOL 10.1K
RES: $37.28SUP: $31.11SMA50: $34.46SMA200: $36.77
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KEQU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
-1.0%/yr Implied 5Y Growth
vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on KEQU today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KEQU. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KEQU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KEQU)
Health Care Rank #87 of 1016
⚔️ BNR vs KEQU Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KEQU vs. BNR, SERA, XGN, TLSI)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Kewaunee Scientific Corporation (KEQU) ranks #87 by composite RQD confidence (69/100, grade C+) and #660 by equity capitalization ($96.8M). Within this direct 5-issuer industry benchmark cohort, KEQU leads on earnings valuation at 10.1x trailing P/E, while KEQU leads on capital efficiency and profitability with 16.7% ROIC and 28.5% gross margin. KEQU currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KEQU
ACTIVE
Kewaunee Scientific Corporation | C+ | 69/100 | 10.1x | 28.5% | 16.7% | -0.21% | $96.8M | Benchmark Subject |
| BNR Burning Rock Biotech Limited | E | 20/100 | — | 74.7% | -35.0% | -1.36% | $115.0M | /bnr-vs-kequ → |
| SERA Sera Prognostics Inc. (Class A) | E | 29/100 | — | -30.0% | -35.0% | -0.97% | $80.5M | /sera-vs-kequ → |
| XGN Exagen Inc. | D- | 36/100 | — | 58.3% | -35.0% | -1.26% | $208.1M | /xgn-vs-kequ → |
| TLSI TriSalus Life Sciences Inc. | E | 30/100 | — | 84.6% | -35.0% | -4.14% | $227.8M | /tlsi-vs-kequ → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0000055529In its most recent audited fiscal period (FY2025, filed 2026-04-30), Kewaunee Scientific Corporation (KEQU) reported GAAP revenue of $282.0M (+17.3% vs. FY2024 revenue of $240.5M , and +38.4% cumulative change since FY2023) , GAAP net income of $9.6M, operating cash flow of $18.6M, and free cash flow of $18.6M (+26.0% YoY). On the balance sheet, KEQU closed FY2025 with $176.0M in total assets against $16.3M in total debt (Altman Z-Score: 3.37, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-04-30 | $282.0M | $9.6M | $18.6M | $18.6M | $176.0M | $16.3M |
| FY2024 (FY) | 2025-04-30 | $240.5M | $11.4M | $14.8M | $14.8M | $189.1M | $35.0M |
| FY2023 (FY) | 2024-04-30 | $203.8M | $18.8M | $19.6M | $19.6M | — | — |
3. KEQU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Kewaunee Scientific Corporation (NASDAQ: KEQU) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $33.44 (-0.21% 1D, market cap $96.8M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, KEQU ranks #87 in composite RQD confidence.
How does KEQU compare to BNR and SERA in the Health Care sector?
Within the Health Care sector (Medical Specialities), KEQU carries a Roarable C+ (69/100 RQD), trailing P/E of 10.1x, gross margin of 28.5%, and ROIC of 16.7%. By comparison, BNR (Burning Rock Biotech Limited) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $115.0M) and SERA (Sera Prognostics Inc. (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $80.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KEQU?
Per KEQU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000055529), Kewaunee Scientific Corporation generated $282.0M in revenue (+17.3% YoY), $9.6M in net income, and $18.6M in free cash flow against $176.0M in total assets and $16.3M in total debt. Key quantitative strengths: Strong cash generator (29% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KEQU trading relative to its 50-day, 200-day, and 52-week technical levels?
KEQU last traded at $33.44 (-0.21% on volume of 10,126 shares), positioning the stock -2.96% below its 50-day simple moving average ($34.46) and -9.06% below its 200-day simple moving average ($36.77). Across its 52-week range of $32.00 to $43.36, KEQU sits at the 12.7% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±4.8% ($31.83 to $35.05).
KEQU Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is KEQU stock moving today?
Why KEQU Stock slipped -0.21% Today — RQD Quant Desk Flash. Solid 29% profit margin (17% return on capital), mixed timing at 10x P/E—hold if owned, no rush to chase.
ROARABLE RATING BRIEF • RQD 69/100 (C+)
✓ STAGE-C NUMBER FIREWALL VERIFIED
KEQU — Kewaunee Scientific Corporation: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:44:13Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, KEQU scores 69 out of 100 with a letter grade of C+ and a verdict of "Roarable Hold — Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine 17/20 (ROIC 16.7%; FCF yield 19.2%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 18/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 12/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 16/20 (Altman Z 3.37; Piotroski F 8/9; Debt/Equity 0.23). For a prospective investor, the strongest pillars are the cash engine and insider conviction, while the weakest is institutional flow at 6/20, indicating limited measured institutional accumulation in the source data. The balance sheet score supports the view that financial stress is not the primary concern. The verdict label signals a neutral posture with a watch for a directional breakout rather than a conviction call in either direction. The 19.2% FCF yield alongside a 10.1 trailing P/E illustrates a valuation tradeoff: cash generation appears high relative to market value, but the source data does not explain whether that yield is sustainable or what drove it.
Snapshot
Business
Kewaunee Scientific Corporation is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry, per the profile section. The source data does not specify its products, customers, or revenue model beyond its reported financial results. Per the FY 2025 filing, revenue was $282.0M, indicating an operating scale in that range.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $282.0M | $16.7M | $9.6M | N/A | $18.6M | $8.2M | $16.3M |
| FY 2024 | $240.5M | $17.8M | $11.4M | N/A | $14.8M | $9.5M | $35.0M |
| FY 2023 | $203.8M | $18.3M | $18.8M | N/A | $19.6M | N/A | N/A |
Per the SEC financials, revenue grew from $203.8M in FY 2023 to $282.0M in FY 2025, while net income declined from $18.8M to $9.6M over the same span. Market data reports a gross margin of 28.5%, operating margin of 5.9%, and net margin of 3.4%, with ROIC of 16.7%. Per the Roarable RQD rating, the Altman Z-Score is 3.37 and the Piotroski F-Score is 8/9. Debt declined from $35.0M in FY 2024 to $16.3M in FY 2025, and the reported Debt/Equity ratio is 0.23.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section, the dominant theme is a planned acquisition of lab dealer NYCOM. Investing.com reports Kewaunee to acquire NYCOM for $55M. A Stock Titan item states a $30M cash payment at closing forms part of the planned acquisition. A Stock Titan headline frames the deal as the U.S.'s largest lab dealer potentially joining Kewaunee. The remaining items are a TradingView estimates report, a Zacks analyst blog mention, and a Stock Traders Daily signal piece, each tagged with a yellow light and "MARKET WIRE" impact label. Risk watch items include the cash component of the acquisition relative to reported cash of $8.2M in FY 2025, and the source data does not state how the balance of consideration is funded. Proprietary signals in the Butterfly Supply-Chain Graph: none.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals recorded. Upstream and downstream dependencies, sector correlations, and bottlenecks are not available in source data. The one ripple the source data does support is that a pending lab-dealer acquisition would connect Kewaunee to distribution activity, though the source data does not detail the mechanics of that connection.
Open Questions
- How will the $55M NYCOM acquisition be financed, given FY 2025 cash of $8.2M and the stated $30M cash payment at closing?
- What drove net income to fall from $18.8M in FY 2023 to $9.6M in FY 2025 while revenue rose?
- What are the company's EPS figures, which are reported as N/A in every period?
- What institutional and insider holders are behind the insider conviction score, given no holders data is provided?
- What products and customers generate the reported revenue?
KEQU Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Kewaunee Scientific Corporation (KEQU) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 18h ago
Kewaunee Scientific Corporation Estimates – NASDAQ:KEQU TradingView report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 21h ago
The Zacks Analyst Blog Highlights Salesforce, S&P Global, Intuit, Kewaunee Scientific and Key Tronic Yahoo Finance report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
The U.S.'s largest lab dealer could join Kewaunee Stock Titan report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com India • 1d ago
Kewaunee Scientific to acquire lab dealer Nycom for $55M By Investing.com Investing.com India report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
Avoiding Lag: Real-Time Signals in (KEQU) Movement Stock Traders Daily report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A $30M cash payment at closing forms part of Kewaunee (KEQU)'s planned NYCOM acquisition. Stock Titan report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.dars.gov.et/ • 1d ago
Kewaunee Scientific (KEQU) Edges Higher to $32.79 as Buyers Defend Support - PCR Extreme https://www.dars.gov.et/ report covering Kewaunee Scientific Corporation (KEQU) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 12d ago
Top Analyst Reports for Salesforce, S&P & Intuit Salesforce, S&P Global and Intuit navigate AI-driven growth opportunities, recurring revenue gains and strategic shifts while facing competition, cost pressures and execution risks.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
KEQU Bull vs. Bear Conversation Board — What's Your Call at $33.44?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KEQU 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $36.19 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is KEQU (C+ • RQD 69/100) a Buy at $33.51?
Welcome to the KEQU (Kewaunee Scientific Corporation) Roar Pit. Current RQD Composite is 69/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Medical Specialities. Bulls point to capital efficiency (16.7% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $25.47 (-24.0%)
Spot @ $33.51 Pump the brakes on KEQU — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on KEQU, but look at what you are paying: 10.1x trailing P/E with 28.5% gross margins. Unless Kewaunee Scientific Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $39.21 (+17.0%)
Spot @ $33.51 KEQU cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on KEQU, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $33.51 (52-wk range $32.00 - $43.36), any beat on forward guidance forces shorts and underweight funds to chase.